Yes, Invitae does confirm variants for both panel and exome testing. We perform orthogonal confirmation of clinically significant findings that do not meet stringent quality metrics—and have done so since we first started our clinical testing service. The confirmation techniques we use include Sanger sequencing, PacBio sequencing of circularized amplicons, array comparative genome hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA).